Nymox Pharmaceutical Corporation has enrolled its first patient for Study NX03-0040, a Phase 2 Study of NX-1207 for low risk localized prostate cancer. NX-1207 is also in Phase 3 development in the U.S. and Europe for benign prostatic hyperplasia (BPH).

Preclinical studies of NX-1207 have shown activity against prostate cancer cells at higher dosage levels of NX-1207 than the dosage used in the current Phase 3 BPH clinical trials. The new study will test both low and high doses of NX-1207 for their effect on low grade localized prostate cancer. Efficacy in the study will be assessed 6 weeks after NX-1207 treatment.

NX-1207 is in late stage Phase 3 development in the U.S. for BPH. Phase 3 trial activities of NX-1207 for BPH have recently begun in Europe sponsored by Recordati S.p.A., the company’s European licensing partner. NX-1207 is administered directly into the prostate by a urologist in an office setting in an injection that does not require anaesthesia, sedation, or catheterization, takes only a few minutes and involves minimal discomfort to the patient. NX-1207 has thus far shown none of the adverse sexual side effects associated with approved medical and surgical treatments for BPH.

The American Cancer Society estimates that in 2012 more than 240,000 men in the United States will be newly diagnosed with prostate cancer and more than 28,000 men will die from the disease. Most cases are detected via prostate-specific antigen (PSA) screening and usually found to have localized tumors. Surgical removal of the prostate (radical prostatectomy) and radiation therapy with or without androgen deprivation therapy are the most common active treatment options for localized prostate cancer but have significant short- and long-term adverse effects, including impotence, urinary dysfunction, and other complications.

Date: June 12, 2012
Source: Nymox Pharmaceutical Corporation